Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company's lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024.
Indaptus Therapeutics, Inc（納斯達克代碼: INDP) 是一家臨床階段生物技術公司，致力於開創創新癌症和病毒感染治療，今天宣佈該公司的首席醫學官Roger Waltzman醫學博士將於2024年6月20日至21日在波士頓舉行的第七屆下一代免疫腫瘤學大會上，就其先導產品候選Decoy20進行更新報告。
Dr. Waltzman will present preliminary results from the Company's ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.
Waltzman博士將介紹公司正在進行的Decoy20第一期研究的初步結果，這是一種使用殺死細菌的靜脈治療，旨在廣泛刺激免疫系統，用於對抗晚期實體瘤患者。
譯文內容由第三人軟體翻譯。